The Advanced Therapies Manufacturing Taskforce has been announced as the recipient of Richard Wilson Impact Award ahead of bioprocess UK.

It has been announced that the winner of the Richard Wilson Impact Award is the Advanced Therapies Manufacturing Taskforce (ATMT), which will be presented at this year’s bioProcessUK conference in Edinburgh. The Richard Wilson Impact Award acknowledges those who are making an impact on the bioprocessing sector. The award is named in honour of Richard Wilson, who was the co-inventor of the Lonza GS system. ATMT was selected as the winner through nominations and then voting from the BIA Manufacturing Advisory Committee and previous award winners.

The Taskforce helped industry to influence government around the Life Sciences Industrial Strategy and had a range of successful outputs. Former chair of the Advanced Therapies Manufacturing Taskforce, Ian McCubbin, said: ‚ÄúOn behalf of the Taskforce it’s an honour to collect this award. The Taskforce was a great team effort, strongly supported by industry, BIA, ABPI and KTN and of course a key part of MMIP activity, and our actions provided strong input into the Life Science Industrial Strategy. Much has been done, the government is listening, and if we can continue to execute our recommendations the UK can be a leading global hub for advanced therapy commercial scale manufacturing.‚Äù

To find out more on the award please click here.

The 15th annual bioProcessUK Conference will be taking place on 20 – 22 November 2018 in Edinburgh. The event will be launched on 20th November with the pre-conference networking evening at Edinburgh Castle. The conference is to take place at the Assembly Rooms, with a Conference dinner at The Hub on 21st November. The previous year’s edition saw more than 285 delegates from 160 organisations in attendance. The Conference offers the perfect platform to hear the latest news, updates and developments from the manufacturing and biologics sphere.

Speakers at the conference will include Steve Bates, CEO of the BioIndustry Association, as well as Dr. Nick Medcalf of Innovate UK who shall be giving an update on ISCF and UKRI, and Chief Manufacturing Officer of the Cell & Gene Therapy Catapult, Dr. Stephen Ward, while Dr. Dave Tudor (Chair of Scottish Life Sciences Industry Leadership Group and Vice-President, Head of Global Manufacturing and Supply Strategy for GlaxoSmithKline) will be presenting the challenges facing the global medicines manufacturing market. An update will also be given on the Medicines Manufacturing Industry Partnership from Andy Evans, Head of AstraZeneca’s Macclesfield Site and Chair of MMIP. To find out more information on Medicines Manufacturing and MMIP please click here or you can join the MMIP LinkedIn Group here.

 

For more information on bioProcessUK, including the full list of speakers and programme, and to register your attendance please click here.

Share this article